Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Serial interval of novel coronavirus (COVID-19) infections

Hiroshi Nishiura, Natalie M. Linton, Andrei R. Akhmetzhanov
doi: https://doi.org/10.1101/2020.02.03.20019497
Hiroshi Nishiura
1Graduate School of Medicine, Hokkaido University, Kia 15 Jo Nishi 7 Chome, Kitaku, Sapporo, 060-8638, Japan
2CREST, Japan Science and Technology Agency, Honcho 4-1-8, Kawaguchi, Saitama, 332-0012 Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nishiurah{at}med.hokudai.ac.jp
Natalie M. Linton
1Graduate School of Medicine, Hokkaido University, Kia 15 Jo Nishi 7 Chome, Kitaku, Sapporo, 060-8638, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrei R. Akhmetzhanov
1Graduate School of Medicine, Hokkaido University, Kia 15 Jo Nishi 7 Chome, Kitaku, Sapporo, 060-8638, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To estimate the serial interval of novel coronavirus (COVID-19) from information on 28 infector-infectee pairs.

Methods We collected dates of illness onset for primary cases (infectors) and secondary cases (infectees) from published research articles and case investigation reports. We subjectively ranked the credibility of the data and performed analyses on both the full dataset (n=28) and a subset of pairs with highest certainty in reporting (n=18). In addition, we adjusting for right truncation of the data as the epidemic is still in its growth phase.

Results Accounting for right truncation and analyzing all pairs, we estimated the median serial interval at 4.0 days (95% credible interval [CrI]: 3.1, 4.9). Limiting our data to only the most certain pairs, the median serial interval was estimated at 4.6 days (95% CrI: 3.5, 5.9).

Conclusions The serial interval of COVID-19 is shorter than its median incubation period. This suggests that a substantial proportion of secondary transmission may occur prior to illness onset. The COVID-19 serial interval is also shorter than the serial interval of severe acute respiratory syndrome (SARS), indicating that calculations made using the SARS serial interval may introduce bias.

Highlights

  • - The serial interval of novel coronavirus (COVID-19) infections was estimated from a total of 28 infector-infectee pairs.

  • - The median serial interval is shorter than the median incubation period, suggesting a substantial proportion of pre-symptomatic transmission.

  • - A short serial interval makes it difficult to trace contacts due to the rapid turnover of case generations.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

H.N. received funding support from Japan Agency for Medical Research and Development [grant number: JP18fk0108050] the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI in Japanese abbreviation) grant nos. 17H04701, 17H05808, 18H04895 and 19H01074, and the Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST) program [grant number: JPMJCR1413]. NML receive graduate study scholarships from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data can be obtained from Supplementary Table.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 17, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Serial interval of novel coronavirus (COVID-19) infections
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Serial interval of novel coronavirus (COVID-19) infections
Hiroshi Nishiura, Natalie M. Linton, Andrei R. Akhmetzhanov
medRxiv 2020.02.03.20019497; doi: https://doi.org/10.1101/2020.02.03.20019497
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Serial interval of novel coronavirus (COVID-19) infections
Hiroshi Nishiura, Natalie M. Linton, Andrei R. Akhmetzhanov
medRxiv 2020.02.03.20019497; doi: https://doi.org/10.1101/2020.02.03.20019497

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (433)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3307)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5168)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3282)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1196)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14647)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4941)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (887)
  • Occupational and Environmental Health (796)
  • Oncology (2526)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (546)
  • Pediatrics (1303)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7522)
  • Radiology and Imaging (1710)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)